Form 4: Eli Lilly Executive Reallocates Deferred Compensation

Eli Lilly & Co. EVP Kenneth Custer reallocated 612.937 phantom stock units within his deferred compensation account, valued at $734.17 per unit.

Summary

• Kenneth L. Custer, EVP & President, Card Met Hlth at Eli Lilly & Co. (LLY), reported a transaction involving his beneficial ownership.
• The transaction, dated August 27, 2025, involved the disposition of 612.937 shares of phantom stock.
• This disposition was a reallocation of funds within Custer's deferred compensation account.
• Each phantom stock unit was valued at $734.17.
• Following this reallocation, Custer directly beneficially owns 2,173.461 shares of phantom stock.
• He also directly beneficially owns 9,346.902 shares of Eli Lilly and Company common stock.
• The phantom stock units represent the right to receive the cash value of one share of common stock and are payable upon termination of employment.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The transaction is a routine reallocation within a deferred compensation account under a 10b5-1 plan, indicating a pre-planned financial management activity rather than a discretionary sale based on new information. It has no direct positive or negative implications for the company's operational performance or immediate stock valuation.

Positives

• The transaction is a reallocation within a deferred compensation account, indicating a structured financial planning move rather than a discretionary open market sale.
• The transaction was made pursuant to a Rule 10b5-1 plan, which suggests it was pre-scheduled and not based on immediate, non-public information.

Negatives

• The disposition of 612.937 phantom stock units, even as a reallocation, reduces the executive's direct exposure to future stock price appreciation for those specific units.

Future Outlook

NA

Industry Context

This is a routine insider transaction disclosure for an executive at a major pharmaceutical company. Such reallocations within deferred compensation plans are common for high-level executives managing their long-term financial portfolios, often under pre-arranged 10b5-1 plans to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Executive compensation structures in the pharmaceutical industry often include various forms of equity-linked awards, such as phantom stock, as part of long-term incentive plans.
• The use of 10b5-1 plans for managing these holdings is a standard practice across industries for executives to manage their personal finances while adhering to insider trading regulations.
• For example, executives at Pfizer (PFE) or Johnson & Johnson (JNJ) also frequently utilize similar deferred compensation and 10b5-1 plan structures for their equity awards.

Related Party Transactions

• Kenneth L. Custer, an executive of Eli Lilly & Co., engaged in a transaction involving the company's phantom stock within his deferred compensation account.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine executive compensation reallocation, not an open market sale or a significant change in overall insider holdings that would signal a shift in confidence.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned reallocation of phantom stock within an executive's deferred compensation account. It does not reflect a discretionary sale based on new information about the company's performance or outlook. Therefore, it provides no new fundamental information to warrant a change in investment recommendation for Eli Lilly & Co. A 'hold' recommendation is appropriate as this filing does not alter the investment thesis.

Keywords

Eli Lilly, LLY, Kenneth Custer, Form 4, Insider Transaction, Phantom Stock, Deferred Compensation, Executive Compensation, Stock Reallocation, 10b5-1 Plan